Business · 02/12/2024Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to PTC Therapeutics for Rare Pediatric Disease Product KEBILIDI
Summary
The FDA has issued a priority review voucher to PTC Therapeutics Inc. for its rare pediatric disease product KEBILIDI (eladocagene exuparvovec-tneq), which was approved on November 13, 2024. The FDA is required to publish notice of the award of the priority review voucher.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →